Breadcrumb

[A19-09] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-01-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 411 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-51] Apalutamide (prostate cancer) - Addendum to Commission A19-09
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-08-01 Extract of dossier assessment 411 kBPDFdownload file
2019-05-02 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V [PDF, 411 kB]

Federal Joint Committee (G-BA)

2019-08-01 A G-BA decision was published.

G-BA documents on this decision

Press releases

2019-05-02 Apalutamide in prostate cancer: indication of considerable added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close